Navigation Links
Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
Date:5/16/2008

ROCHESTER, Minn. -- Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive intravenous calcium and magnesium before and after the chemotherapy drug oxaliplatin for the treatment of advanced colon cancer experience a significantly reduced incidence and severity of neurological side effects (neurotoxicity). This reduction increases the likelihood that patients are able to complete a full course of treatment. The findings were released May 15 as part of the 44th annual meeting of the American Society of Clinical Oncology.

There have been limited studies and anecdotal stories about the effectiveness of calcium plus magnesium in reducing neurotoxicity caused by oxaliplatin, says Daniel Nikcevich, M.D., Ph.D., an oncologist at St. Marys Duluth Clinic in Duluth, Minn., a member of NCCTG and study co-chair.

We designed a double-blind, placebo-controlled study that confirmed the effectiveness of calcium plus magnesium in reducing debilitating neurological sensitivity associated with oxaliplatin, such as pain in the hands, fingers, feet and toes. In the past, these side effects have caused patients to stop treatment and, therefore, not receive critical therapy.

Each year in the United States, 150,000 patients are diagnosed with colon cancer, and approximately 50 percent of those develop advanced colon cancer. Oxaliplatin, in combination with other chemotherapy drugs such as 5-fluorouracil (5-FU), has emerged as a standard-of-care of first-line therapy for advanced colon cancer. However, oxaliplatin can cause both acute and chronic cumulative sensory neurological problems including pain, numbness and tingling that can prevent patients from completing treatment.

In the study, 50 of the 102 patients enrolled received intravenous calcium and magnesium along with oxaliplatin-based chemotherapy, while 52 patients received oxaliplatin-based adjuvant chemotherapy for colon cancer and an intravenous placebo. Study results showed that the use of calcium and magnesium infusions before and after oxaliplatin was associated with a significant decrease in the incidence and severity of neurotoxicity, and it also delayed the time to the onset of neurotoxicity on oxaliplatin therapy.

Calcium and magnesium are an easily administered, safe treatment option for oxaliplatin-induced neurotoxicity. Some initial reports from other studies claimed that the use of calcium and magnesium reduced the activity of oxaliplatin-based chemotherapy, says Axel Grothey, M.D., an oncologist at Mayo Clinic and study co-chair. However, we have definitive results from an independent, blinded radiologic review which demonstrates no negative influence of calcium and magnesium on the outcome for oxaliplatin-based chemotherapy.

Now that we have shown the effectiveness of calcium and magnesium in reducing oxaliplatin-induced neurotoxicity, a further step may be to evaluate the benefit of calcium and magnesium in reducing neurotoxicity caused by other medications, says Dr. Nikcevich. Many other commonly used chemotherapy agents cause neurological sensitivity. By applying our study design, we can test the effectiveness of calcium and magnesium when used with other treatments.

This study was done as part of a program coordinated by Charles Loprinzi, M.D., a medical oncologist at Mayo Clinic Rochester. The program he leads has conducted more than 50 clinical trials designed to find ways to prevent or treat untoward symptoms related to cancer and cancer therapy. This includes three trials to evaluate ways to treat established neuropathy caused by chemotherapy and three additional studies to try to prevent such toxicity. Additional trials are in development to find other ways to alleviate this toxicity.


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
2. Study suggests blood test can help improve treatment outcomes for breast cancer patients
3. Study takes a step toward better defining fatigue
4. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
5. Study finds parents use cough medicines on under-2s despite the warnings
6. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
7. Study Supports Popular HIV Drug Regimen
8. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
9. Study shows that prostate cancer increases the risk of bone fracture
10. Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
11. Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology: